PARIS--(BUSINESS WIRE)--Regulatory News:
“Following the improved sales expectations and the savings resulting from discontinuation of all developments with tasquinimod in prostate cancer, we raise our sales and profitability guidance for 2015.”
Ipsen (Euronext: IPN; ADR: IPSEY) today reported its sales for the first quarter 2015.
Help employers find you! Check out all the jobs and post your resume.
